Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Clinical trial NCT03269669 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03269669
- Sponsor
- National Cancer Institute (NCI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-01-23
- Primary completion
- 2025-12-31
- Enrollment
- 73
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.